1606126-53-7

Upstream product

• 1606126-50-4 N-[3-(3-fluorophenyl)-4-iodo-1H-pyrazol-5-yl]acetamide 
• 1606126-51-5 N-[3-(3-fluorophenyl)-4-(2-phenylethynyl)-1H-pyrazol-5-yl]acetamide 
• 1606126-52-6 3-(3-fluorophenyl)-4-(2-phenylethynyl)-1H-pyrazol-5-amine 
• 766519-89-5 5-(3-fluoro-phenyl)-2H-pyrazol-3-ylamine 
• 1606126-49-1 N-[3-(3-fluorophenyl)-1H-pyrazol-5-yl]acetamide 

Downstream Products

• 1606126-31-1 4-[2-[4-chloro-3-(3-fluorophenyl)-5-phenyl-pyrazolo[3,4-c]pyridazin-1-yl]ethyl]morpholine 
• 1606126-30-0 4-chloro-3-(3-fluorophenyl)-1-[2-(4-methylpiperazin-1-yl)ethyl]-5-phenyl-pyrazolo[3,4-c]pyridazine 

Relevant academic research and scientific papers

PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME

Compounds, compositions and methods for the treatment of retinal degenerative diseases, such as retinitis pigmentosa, Leber's congenital Amaurosis, Syndromic retinal degenerations, age-related macular degeneration and Usher Syndrome, and hearing loss associated with Usher Syndrome are described herein.

PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME

Compounds, compositions and methods for the treatment of retinal degenerative diseases, such as retinitis pigmentosa, Leber's congenital Amaurosis, Syndromic retinal degenerations, age-related macular degeneration and Usher Syndrome, and hearing loss associated with Usher Syndrome are described herein.